Popular on eTradeWire
- Eduscape and Engino Join Forces to Solve the "E" Challenge in STEM Education - 336
- Southern Utah Retreats: The Hottest Retreat Center in the Southwest - 253
- Tevye in New York! at North Coast Rep Variety Nights - 251
- Local Roofer Advises OKC Homeowners on Hail-Resistant Roofing Options Following Recent Storms - 236
- TicketMeta and TechStorm Forge Strategic Partnership to Revolutionize Esports Event Experiences - 222
- Theralist Celebrates One Year Anniversary of Launch with Impressive Growth and Expansion - 211
- Another Reagan AP Accident; AI to the Rescue? - 206
- One Home Service Names Atlantic Harbor as Broward County's #1 Marine Construction Company - 193
- Revolutionary Partnership Bridging AI/Youth Sports/Business - 181
- Over 9,000 Users Trust QBSwift for Reliable QuickBooks Solutions - 169
Similar on eTradeWire
- YourEggs Egg Donation Bank Launches Pride Eggs: A New Division Dedicated to Celebrating and Supporting LGBTQ+ Families
- Stay Injury-free While Gardening This Season
- Allergy, Asthma and Immunology Center Welcomes Dr. Karthik R. Krishnan, MD to Its Expanding Team
- Care Dental Implant & Cosmetic Center's New Website Launch!
- $4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression, PTSD: NRx: Stock Symbol: NRXP
- W. Scout Robinson, MD, Joins AAIC - Allergy, Asthma and Immunology Center
- Tamala Baldwin and BLKG TV Host Free Screenwriting Wellness Workshop in Gwinnett
- Kwizda Pharma Adopts CARA Life Sciences Platform for Rapid QMS Implementation with Minimal IT Resources
- Wright Smiles Highlights the Importance of Saving Natural Teeth During Root Canal Awareness Week
- Save Your Smile Eagle: Root Canal Treatment Awareness at Castlebury Dental
OncoBeta announces the expansion of Rhenium-SCT for non-melanoma skin cancer patients in Italy
eTradeWire News/10777441
BOZEN, Italy - eTradeWire -- OncoBeta®, a leading medical device company specialising in innovative epidermal radioisotope therapies, has announced the expansion of Rhenium-SCT® (Skin Cancer Therapy) treatment services in Italy with the Bolzano Hospital the latest to come on board. This marks a significant advancement in the availability of non-melanoma skin cancer (NMSC) treatment options within the country.
Rhenium skin cancer therapy is an advanced radionuclide therapy that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly over the NMSC lesion, targeting cancer cells without the need for surgery.1,4
Dr. Mohsen Farsad at Bolzano Hospital has been impressed with the Rhenium-SCT device, noting, "I have witnessed impressive outcomes with several patients treated here in Italy already, and am pleased with the design of the device technology."
"Rhenium skin cancer therapy fulfills many patients' desires for a non-surgical alternative for the treatment of NMSCs especially in relation to difficult localisations. I am pleased to continue treating suitable patients with Rhenium-SCT", adds Dr. Farsad.
Shannon D. Brown III, CCO at OncoBeta, says, "While surgical intervention remains the standard-of-care for NMSC treatment, it often leads to suboptimal outcomes. Rhenium-SCT offers a non-surgical alternative with a simple application directly to the area needed to treat, and allows patients to resume their daily activities with minimal disruption."
According to GLOBOCAN estimates, the number of new NMSC cases in Italy is projected to rise from 29,000 to 41,700 between 2022 and 2045.5 Epidemiological data for Europe shows an annual incidence rate of NMSCs at 129.3 cases per 100,000 men and 90.8 per 100,000 women. Basal cell carcinoma (BCC) accounts for approximately 15% of all diagnosed cancers in Italy, with an annual incidence of around 100 cases per 100,000 inhabitants.6
Dr. Gerhard Dahlhoff, Medical Director at OncoBeta, emphasised, "Rhenium-SCT enables targeted, non-invasive treatment of NMSCs while preserving adjacent healthy tissue. This patient-friendly approach underscores our commitment to enhancing treatment options for those affected by NMSCs."
More on eTradeWire News
Rhenium-SCT is currently available in Germany, Austria, Switzerland, Italy, Spain, United Kingdom, South Africa and Australia. Rhenium-SCT will be provided to patients at Bolzano Hospital by OncoBeta's distribution partner, DSD Pharma.
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4
The Rhenium-SCT is a painless,*1,2 single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,7 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,7 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,7,8
About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
More on eTradeWire News
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
About DSD Pharma
DSD Pharma is a distributor for diagnostics, theranostics and radiopharmaceutical/medical devices in the field of nuclear medicine and radiopharmaceuticals. DSD Pharma offers a product portfolio developed together at the forefront of research to its customers. This ensures the safety of latest technologies for the HCP and the best available diagnosis/theranosis/therapy for the patient.
Find out more about DSD Pharma at www.dsd-pharma.com
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions treated.3
‡A treatment is considered non-invasive when no cut or break in the skin is created.9
References
Rhenium skin cancer therapy is an advanced radionuclide therapy that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly over the NMSC lesion, targeting cancer cells without the need for surgery.1,4
Dr. Mohsen Farsad at Bolzano Hospital has been impressed with the Rhenium-SCT device, noting, "I have witnessed impressive outcomes with several patients treated here in Italy already, and am pleased with the design of the device technology."
"Rhenium skin cancer therapy fulfills many patients' desires for a non-surgical alternative for the treatment of NMSCs especially in relation to difficult localisations. I am pleased to continue treating suitable patients with Rhenium-SCT", adds Dr. Farsad.
Shannon D. Brown III, CCO at OncoBeta, says, "While surgical intervention remains the standard-of-care for NMSC treatment, it often leads to suboptimal outcomes. Rhenium-SCT offers a non-surgical alternative with a simple application directly to the area needed to treat, and allows patients to resume their daily activities with minimal disruption."
According to GLOBOCAN estimates, the number of new NMSC cases in Italy is projected to rise from 29,000 to 41,700 between 2022 and 2045.5 Epidemiological data for Europe shows an annual incidence rate of NMSCs at 129.3 cases per 100,000 men and 90.8 per 100,000 women. Basal cell carcinoma (BCC) accounts for approximately 15% of all diagnosed cancers in Italy, with an annual incidence of around 100 cases per 100,000 inhabitants.6
Dr. Gerhard Dahlhoff, Medical Director at OncoBeta, emphasised, "Rhenium-SCT enables targeted, non-invasive treatment of NMSCs while preserving adjacent healthy tissue. This patient-friendly approach underscores our commitment to enhancing treatment options for those affected by NMSCs."
More on eTradeWire News
- Global Learning Charter Public School to Hold Annual Global Gala Scholarship Fundraiser on May 9th
- PAG Law Represents Expeditionary Engineering Inc. in Strategic Acquisition by Ultra Intelligence & Communications
- Ketcham Racing Hosts Spring Car Show
- YourEggs Egg Donation Bank Launches Pride Eggs: A New Division Dedicated to Celebrating and Supporting LGBTQ+ Families
- Indie Game Publisher Joins Federal Lawsuit Challenging Trump Administration's Illegal Tariffs
Rhenium-SCT is currently available in Germany, Austria, Switzerland, Italy, Spain, United Kingdom, South Africa and Australia. Rhenium-SCT will be provided to patients at Bolzano Hospital by OncoBeta's distribution partner, DSD Pharma.
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4
The Rhenium-SCT is a painless,*1,2 single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,7 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,7 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,7,8
About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
More on eTradeWire News
- StablePayLabs Introduces Advanced Micropayment Solution with Blockchain, DAOs, and Stablecoins
- Day On The Farm: Santa Ynez Valley Historical Museum Tour
- New Children's Ebook and Paperback "Erica Collins: Graduation Speech"
- Bennett Awards Brings Conceptual Vision to Life with Groundbreaking College Basketball Crown Trophy
- Union Avenue Opera Prepares Powerful 2025 Festvial Season
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
About DSD Pharma
DSD Pharma is a distributor for diagnostics, theranostics and radiopharmaceutical/medical devices in the field of nuclear medicine and radiopharmaceuticals. DSD Pharma offers a product portfolio developed together at the forefront of research to its customers. This ensures the safety of latest technologies for the HCP and the best available diagnosis/theranosis/therapy for the patient.
Find out more about DSD Pharma at www.dsd-pharma.com
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions treated.3
‡A treatment is considered non-invasive when no cut or break in the skin is created.9
References
- Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48: 1511–1521.
- Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.
- Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.
- Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.
- Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
- Sordi E, et al. Epidemiologia. 2024;5:1–10.
- Cipriani C, et al. International J Nucl Med. 2017; July:114–112.
- Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745–749.
- Australian Therapeutic Goods Administration. Acronym and glossary of terms. Available at: https://www.tga.gov.au/resources/acronyms-and-glossary-terms. (Accessed June 2024).
Source: OncoBeta GmbH
0 Comments
Latest on eTradeWire News
- $4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression, PTSD: NRx: Stock Symbol: NRXP
- L-Tron heads to the 2025 IACP Technology Conference in Indianapolis, IN
- Local Roofer Urges Blanchard Homeowners to Schedule Roof Inspections After Severe Hail Storm
- Miami Valley Urban League Announces their 2025 Pillar Award Recipients
- W. Scout Robinson, MD, Joins AAIC - Allergy, Asthma and Immunology Center
- CryoStork®: The Series of Dry Shippers
- FAN EXPO Philadelphia and School District Team Up to Spotlight Young Artists at Major Convention
- Creative Colony Spaces Launches Dedicated Office and Community Support Program for Nonprofits in Silver Spring
- CIMdata to Join a Web Session Covering Key Topics at the Forefront of the Current PLM Landscape
- Tamala Baldwin and BLKG TV Host Free Screenwriting Wellness Workshop in Gwinnett
- Kwizda Pharma Adopts CARA Life Sciences Platform for Rapid QMS Implementation with Minimal IT Resources
- YMCA Seeks to Expand Civic Leadership Opportunities for More New Jersey Youth
- Swim Stroke Doctor, Secures Patent for Groundbreaking Swim Cap That Improves Performance Through
- Solar Refrigerator Company Price Cuts on Danfoss Secop, Solar Lithium Batteries & Solar Fridges
- PulteGroup Gifts New Mortgage-Free Home to Jacksonville Veteran and Purple Heart Recipient
- Wasatch-Labs.net, a Draper Utah based Skin & Dental Care Contract Manufacturer, Aligns with Las Vegas' Reborn Consultants to Boost Private-Label Sales
- Anern Launches New Generation of Lithium Solar Batteries, Empowering a Smarter, Greener Future
- Wright Smiles Highlights the Importance of Saving Natural Teeth During Root Canal Awareness Week
- Save Your Smile Eagle: Root Canal Treatment Awareness at Castlebury Dental
- Comfort Meets Care: Market Street Dental Studio Debunks Root Canal Myths During Awareness Week